A Structural Analysis of Glycosaminoglycans from Lethal and Nonlethal Breast Cancer Tissues: Toward a Novel Class of Theragnostics for Personalized Medicine in Oncology?
Restricted accessResearch articleFirst published online March, 2012
A Structural Analysis of Glycosaminoglycans from Lethal and Nonlethal Breast Cancer Tissues: Toward a Novel Class of Theragnostics for Personalized Medicine in Oncology?
Cancer is one of the leading noncommunicable diseases that vastly impacts both developed and developing countries. Truly innovative diagnostics that inform disease susceptibility, prognosis, and/or response to treatment (theragnostics) are seriously needed for global public health and personalized medicine for patients with cancer. This study examined the structure and content of glycosaminoglycans (GAGs) in lethal and nonlethal breast cancer tissues from six patients. The glycosaminoglycan content isolated from tissue containing lethal cancer tumors was approximately twice that of other tissues. Molecular weight analysis showed that glycosaminoglycans from cancerous tissue had a longer weight average chain length by an average of five disaccharide units, an increase of approximately 15%. Dissacharide analysis found differences in sulfation patterns between cancerous and normal tissues, as well as sulfation differences in GAG chains isolated from patients with lethal and nonlethal cancer. Specifically, cancerous tissue showed an increase in sulfation at the “6S” position of CS chains and an increase in the levels of the HS disaccharide NSCS. Patients with lethal cancer showed a decrease in HS sulfation, with lower levels of “6S” and higher levels of the unsulfated “0S” disaccharide. Although these findings come from a limited sample size, they indicate that structural changes in GAGs exist between cancerous and noncancerous tissues and between tissues from patients with highly metastatic cancer and cancer that was successfully treated by chemotherapy. Based on these findings, we hypothesize that (1) there are putative changes in the body's construction of GAGs as tissue becomes cancerous; (2) there may be innate structural person-to-person variations in GAG composition that facilitate the metastasis of tumors in some patients when they develop cancer.
Get full access to this article
View all access options for this article.
References
1.
AliniM., LosaG.A.1991. Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breask tissues. Cancer Res., 51:1443–1447.
BlackhallF.H., MerryC.L.R., DaviesE.J., JaysonG.C.2001. Heparan sulfate proteoglycans and cancer. Br. J. Cancer, 85:1094–1098.
5.
BulowH.E., HobertO.2006. The molecular diversity of glycosaminoglycans shapes animal development. Annu. Rev. Cell Dev. Biol., 22:375–407.
6.
CorteM.D., GonzalezL.O., LamelasM.L., AlvarezA., JunqueraS., AllendeM.T.et al.2006. Expression and clinical signification of cytosolic hyaluronan levels in invasive breast cancer. Breast Cancer Res. Treat., 97:329–337.
7.
CorteM.D., GonzalezL.O., JunqueraS., BongeraM., AllendeM.T., VizosoF.J.2010. Analysis of the expression of hyaluronan in intraductal and invasive carcinomas of the breast. J. Cancer Res. Clin. Oncol., 136:745–750.
8.
DeleheddeM., DeudonE., BoillyB., HondermarckH.1996. Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity in human breast cancer cells. Exp. Cell Res., 229:398–406.
9.
DietrichC.P., SampaioL.O., ToledoO.M.S.1976. Characteristic distribution of sulfated mucopolysaccharides in different tissues and in their respective mitochondria. Biochem. Biophys. Res. Commun., 71:1–10.
10.
DietrichC.P., SampaioL.O., ToledoO.M.S., CassaroC.M.F.1977. Cell recognition and adhesiveness—possible biological role for sulfated mucopolysaccharides. Biochem. Biophys. Res. Commun., 75:329–336.
11.
EdensR.E., AlhakimA., WeilerJ.M., RethwischD.G., FareedJ., LinhardtR.J.1992. Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low molecular weight heparin derivatives. J. Pharm. Sci., 81:823–827.
12.
EskoJ.D., SelleckS.B.2002. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem., 71:435–471.
13.
FjeldstadK., KolsetS.O.2005. Decreasing the metastatic potential in cancers—targeting the heparan sulfate proteoglycans. Curr. Drug Targets, 6:665–680.
14.
FujiiM., YusaA., YokoyamaY., KokuryoT., TsunodaN., OdaK.et al.2010. Cytoplasmic expression of the JM403 antigen GlcA-GlcNH(3)(+) on heparan sulfate glycosaminoglycan in mammary carcinomas—a novel proliferative biomarker for breast cancers with high malignancy. Glycoconj. J., 27:661–672.
15.
GodavartiR., DavisM., VenkataramanG., CooneyC., LangerR., SasisekharanR.1996. Heparinase III from Flavobacterium heparinum: cloning and recombinant expression in Escherichia coli. Biochem. Biophys. Res. Commun., 225:751–758.
16.
GotteM., YipG.W.2006. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res., 66:10233–10237.
17.
GressnerA.M.1983. Hepatic proteoglycans—a brief survey of their patho-biochemical implications. Hepato-Gastroenterology, 30:225–229.
18.
GuoC.H., KooC.Y., BayB.H., TanP.H., YipG.W.2007. Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour. Int. J. Oncol., 31:1415–1423.
19.
Herrera-GayolA., JothyS.2001. Effects of hyaluronan on the invasive properties of human breast cancer cells in vitro. Int. J. Exp. Pathol., 82:193–200.
20.
IrimuraT., NakajimaM., NicolsonG.L.1986. Chemically modified heparins as inhibitors of heparan-sulfate specific endo-beta-glucurongdase (heparanase) of metastatic melanoma-cells. Biochemistry, 25:5322–5328.
21.
ItanoN., KimataK.2008. Altered hyaluronan biosynthesis in cancer progression. Semin. Cancer Biol., 18:268–274.
22.
KnutsonJ. R., IidaJ., FieldsG.B., McCarthyJ.B.1996. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol. Biol. Cell, 7:383–396.
23.
KooC.Y., BayB.H., LuiP.C.W., TseG.M.K., TanP.H., YipG.W.C.2006. Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors. Modern Pathol., 19:1344–1350.
24.
KramerM.W., GolshaniR., MerseburgerA.S., KnappJ., GarciaA., HennenlotterJ.et al.2010. HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur. Urol., 57:86–93.
25.
LeeC.M., TanakaT., MuraiT., KondoM., KimuraJ., SuW.et al.2002. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res., 62:4282–4288.
26.
Levy-AdamF., IlanN., VlodavskyI.2010. Tumorigenic and adhesive properties of heparanase. Semin. Cancer Biol., 20:153–160.
27.
LinhardtR.J., ToidaT.2004. Role of glycosaminoglycans in cellular communication. Acc. Chem. Res., 37:431–438.
28.
LokeshwarV.B., ObekC., SolowayM.S., BlockN.L.1997. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res., 57:773–777.
29.
LokeshwarV.B., YoungM.J., GoudarziG., IidaN., YudinA.I., CherrG.N.et al.1999. Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Cancer Res., 59:4464–4470.
30.
LokeshwarV.B., RubinowiczD., SchroederG.L., ForgacsE., MinnaJ.D., BlockN.L.et al.2001. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J. Biol. Chem., 276:11922–11932.
31.
LvH.Z., YuG.L., SunL.L., ZhangZ., ZhaoX., ChaiW.G.2007. Elevate level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma. Oncology, 72:347–356.
32.
MellorP., HarveyJ.R., MurphyK.J., PyeD., O'BoyleG., LennardT.W.J.et al.2007. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br. J. Cancer, 97:761–768.
33.
MuramatsuT., MuramatsuH.2008. Glycosaminoglycan-binding cytokines as tumor markers. Proteomics, 8:3350–3359.
34.
NakajimaM., IrimuraT., DiferranteD., DiferranteN., NicolsonG.L.1983. Heparan-sulfate degradation—relation to tumor invasive and metastatic properties of mouse B-16 melanoma sublines. Science, 220:611–613.
35.
NurcombeV., SmartC.E., ChipperfieldH., CoolS.M., BoillyB., HondermarckH.2000. The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates J. Biol. Chem., 275:30009–30018.
36.
PaivaP., Van DammeM.P., TellbachM., JonesR.L., JoblingT., SalamonsenL.A.2005. Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecol. Oncol., 98:193–202.
37.
PhamH.T., BlockN.L., LokeshwarV.B.1997. Tumor-derived hyaluronidase: a diagnostic urine marker for high grade bladder cancer. Cancer Res., 57:778–783.
38.
PlattV.M., SzokaF.C.2008. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharmaceut., 5:474–486.
RicciardelliC., QuinnD.I., RaymondW.A., McCaulK., SutherlandP.D., StrickerP.D.et al.1999. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res., 59:2324–2328.
41.
SakkoA.J., ButlerM.S., ByersS., ReinbothB.J., StahlJ., KenchJ.G.et al.2008. Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol. Biomarkers Prevent., 17:2488–2497.
42.
SampaioL.O., DietrichC.P., FilhoO.G.1977. Changes in sulfated mucopolysaccharide composision of mammalian-tissues during growth and in cancer tissues. Biochim. Biophys. Acta, 498:123–131.
43.
SasisekharanR., ShriverZ., VenkataramanG., NarayanasamiU.2002. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer, 2:521–528.
44.
SchonherrE., JarvelainenH.T., KinsellaM.G., SandellL.J., WightT.N.1993. Platelet-derived growth-factor and transforming growth-factor-beta-1 differentially affect the syntesis of biglycan and decorin by monkey arterial smooth-muscle cells. Arterioscler. Thromb., 13:1026–1036.
45.
ShayaD., TociljA., LiY.G., MyetteJ., VenkataramanG., SasisekharanR.et al.2006. Crystal structure of heparinase II from Pedobacter heparinus and its complex with a disaccharide product. J. Biol. Chem., 281:15525–15535.
46.
SimpsonM.A., WilsonC.M., McCarthyJ.B.2002. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am. J. Pathol., 161:849–857.
47.
SolakyildirimK., ZhangZ.Q., LinhardtR.J.2010. Ultraperformance liquid chromatography with electrospray ionization ion trap mass spectrometry for chondroitin disaccharide analysis. Anal. Biochem., 397:24–28.
48.
TengY.H.F., TanP.H., ChiaS.J., ZamN., LauW.K.O., ChengC.W.S.et al.2008. Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer. Mod. Pathol., 21:893–901.
49.
The Lancet Oncology (Editorial). 2011. Two days in New York: reflections on the UN NCD Summit. Lancet Oncol., 12:981.
50.
ToidaT., YoshidaH., ToyodaH., KoshishiI., ImanariT., HilemanR.E.et al.1997. Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and species. Biochem. J., 322:499–506.
51.
VizosoF.J., del CasarJ.M., CorteM.D., GarciaI., CorteM.G., AlvarezA.et al.2004. Significance of cytosolic hyaluronan levels in gastric cancer. Eur. J. Surg. Oncol., 30:318–324.
52.
VlodavskyI., FriedmannY., ElkinM., AingornH., AtzmonR., Ishai-MichaeliR.et al.1999. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat. Med., 5:793–802.
53.
WestlingC., LindahlU.2002. Location of N-unsubstituted glucosamine residues in heparan sulfate. J. Biol. Chem., 277:49247–49255.
54.
YangB., WeyersA., BaikJ.Y., SternerE., SharfsteinS., MousaS.A.et al.2011. Ultra-performing ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal. Biochem., 415:59–66.
55.
YipG.W., SmollichM., GotteM.2006. Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Res., 5:2139–2148.
56.
YoshidaE., ArakawaS., MatsunagaT., ToriumiS., TokuyamaS., MorikawaK.et al.2002. Cloning, sequencing, and expression of the gene from Bacillus circulans that codes for a heparinase that degrades both heparin and heparan sulfate. Biosci. Biotechnol. Biochem., 66:1873–1879.
57.
ZhangF.M., SunP.L., MunozE., ChiL.L., SakaiS., ToidaT.et al.2006. Microscale isolation and analysis of heparin from plasma using an anion-exchange spin column. Anal. Biochem., 353:284–286.
